Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3927 | oropharyngeal and intestinal microbiota Wiki | 1.00 |
drug3806 | host immune factors Wiki | 1.00 |
drug1013 | Diagnostic examination for venous thromboembolism Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D054556 | Venous Thromboembolism NIH | 0.33 |
D020246 | Venous Thrombosis NIH | 0.30 |
D011655 | Pulmonary Embolism NIH | 0.26 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002625 | Deep venous thrombosis HPO | 0.30 |
HP:0002204 | Pulmonary embolism HPO | 0.26 |
HP:0001907 | Thromboembolism HPO | 0.21 |
Navigate: Correlations HPO
There is one clinical trial.
Patients hospitalized for COVID-19 may need intensive care (e.g. mechanical ventilation) during hospitalization. Some risk factors are already known but better targeting of such patients is still needed, at least because existing risk factors are not strong enough to provide an accurate prediction. Care organization would benefit for such a predictive tool. Oropharyngeal and gut microbiota could potentially fill a significant gap in predictive performances. The investigators therefore propose to sample 200 patients (oropharyngeal and rectal swab) admitted in infectious disease department at Bichat Hospital and at high risk of needing intensive care during hospitalization. The investigators plan to perform metagenomic sequencing and bioinformatic analysis of these samples to characterize the diversity of bacterial species present in the oropharynx and the gut and to identify new factors associated with the need for intensive care. Aside metagenomic analyses, The investigators will perform semi-quantitative cultures of the oropharyngeal and gut microbiota to identify and quantify pathogens in order to predict the risk of bacterial infections in COVD-19 patients. For patients transferred in intensive care unit, The investigators will to perform another series of samples to better characterize the evolution of microbiota during mechanical ventilation and identify factors associated with the risk of developing a ventilator-associated pneumonia. Microbiota data will be considered together with the host genotype, the viral sequence and a deep immunological profiling to identify the main determinants of the evolution toward severity of COVID-19.
Description: The main endpoint is the indication of worsening of the general condition
Measure: identify risk factors associated with severe forms of COVID-19 Time: day 14Description: composition of the gut microbiota on admission to intensive care to predict the outcome of severe COVID-19 in patients transferred to the ICU (subgroup analysis);
Measure: link between the composition of the gut microbiota and admission to intensive care Time: 3 monthsDescription: predictive performance of semi-quantitative culture and rapid metagenomic evaluation of the oropharyngeal microbiota to predict the occurrence of VAP in patients admitted to an ICU and mechanically ventilated (subgroup analysis).
Measure: predictive performance of semi-quantitative culture and rapid metagenomic evaluation Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports